The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Under the terms of the agreement, Nxera is eligible to receive development and commercial milestones totalling up to US$694 million, plus tiered royalties on global sales.

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Misinterpretation of MRI findings by clinicians focused on earlier intervention is leading to increased rates of ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Big Pharma is using dark money to fund groups that sound like patient advocacy organizations but represent the industry.

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index ...

Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic jolt that could accelerate the city’s ambitions to become a national ...